Sarepta discontinues development of Duchenne ASO treatment vesleteplirsen
The US biopharma will discontinue development of the Exondys 51 (eteplirsen) follow up treatment to focus on other treatment candidates.
Archives for November 7, 2024
Novo Nordisk signs $285 million deal for a once-monthly GLP-1 receptor agonist
Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.
Aditum Bio and Leads Biolabs join forces in new company to fight autoimmune diseases
The two companies have formed Oblenio Bio to develop a tri-specific T-cell engager